Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency

2014, Prevalence of rare diseases: bibliographic data listed in order of decreasing prevalence or number of published cases McGovern, 2008, A prospective, cross-sectional survey study of the natural history of Niemann–Pick disease type B, Pediatrics, 122, e341, 10.1542/peds.2007-3016 Schuchman, 2013, Niemann–Pick disease types A and B: acid sphingomyelinase deficiencies McGovern, 2006, Natural history of type A Niemann–Pick disease: possible endpoints for therapeutic trials, Neurology, 66, 228, 10.1212/01.wnl.0000194208.08904.0c McGovern, 2013, Morbidity and mortality in type B Niemann–Pick disease, Genet. Med., 15, 618, 10.1038/gim.2013.4 Wasserstein, 2004, The natural history of type B Niemann–Pick disease: results from a 10-year longitudinal study, Pediatrics, 114, e672, 10.1542/peds.2004-0887 Wasserstein, 2013, Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B, J. Inherit. Metab. Dis., 36, 123, 10.1007/s10545-012-9503-0 Miranda, 2000, Infusion of recombinant human acid sphingomyelinase into Niemann–Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology, FASEB J., 14, 1988, 10.1096/fj.00-0014com Murray, 2015, Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency: The utility of animal models of disease in the toxicological evaluation of potential therapeutics, Mol. Genet. Metab., 114, 217, 10.1016/j.ymgme.2014.07.005 McGovern, 2015, Novel first-dose adverse drug reactions during a phase 1 trial of recombinant human acid sphingomyelinase (rhASM) in adults with Niemann–Pick disease type B (acid sphingomyelinase deficiency), Genet. Med. Thurberg, 2012, Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann–Pick disease type B), Am. J. Surg. Pathol., 36, 1234, 10.1097/PAS.0b013e31825793ff Mendelson, 2006, Type B Niemann–Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing, Radiology, 238, 339, 10.1148/radiol.2381041696 Miller, 2005, Standardisation of spirometry, Eur. Respir. J., 26, 319, 10.1183/09031936.05.00034805 Mendoza, 1999, The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory, Cancer, 85, 1186, 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N Cleeland, 1994, Pain assessment: global use of the Brief Pain Inventory, Ann. Acad. Med. Singap., 23, 129 Cleeland, 2002, Pain assessment: the advantages of using pain scales in lysosomal storage diseases, Acta Paediatr. Suppl., 91, 43, 10.1111/j.1651-2227.2002.tb03109.x Odze, 2004 Hankinson, 1999, Spirometric reference values from a sample of the general U.S. population, Am. J. Respir. Crit. Care Med., 159, 179, 10.1164/ajrccm.159.1.9712108 Miller, 1983, Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history, Am. Rev. Respir. Dis., 127, 270 Legnini, 2012, Analysis of acid sphingomyelinase activity in dried blood spots using tandem mass spectrometry, Ann. Lab. Med., 32, 319, 10.3343/alm.2012.32.5.319 Zhang, 2008, Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry, Clin. Chem., 54, 1725, 10.1373/clinchem.2008.104711 Pastores, 2004, Therapeutic goals in the treatment of Gaucher disease, Semin. Hematol., 41, 4, 10.1053/j.seminhematol.2004.07.009 Mozaheb, 2011, Iron balance in regular blood donors, Transfus. Med. Hemother., 38, 190, 10.1159/000328812 Pellegrino, 2005, Interpretative strategies for lung function tests, Eur. Respir. J., 26, 948, 10.1183/09031936.05.00035205 Richards, 2002, Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders, Clin. Appl. Immunol. Rev., 2, 241, 10.1016/S1529-1049(02)00049-1 Starzyk, 2007, The long-term international safety experience of imiglucerase therapy for Gaucher disease, Mol. Genet. Metab., 90, 157, 10.1016/j.ymgme.2006.09.003 Jones, 2008, Characterization of common SMPD1 mutations causing types A and B Niemann–Pick disease and generation of mutation-specific mouse models, Mol. Genet. Metab., 95, 152, 10.1016/j.ymgme.2008.08.004 Reid, 2010, Characterization of and risk factors for the acute-phase response after zoledronic acid, J. Clin. Endocrinol. Metab., 95, 4380, 10.1210/jc.2010-0597 Spiegel, 1996, Signal transduction through lipid second messengers, Curr. Opin. Cell Biol., 8, 159, 10.1016/S0955-0674(96)80061-5 Gulbins, 2004, Ceramide, membrane rafts and infections, J. Mol. Med. (Berl.), 82, 357, 10.1007/s00109-004-0539-y Schissel, 1998, Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development, J. Biol. Chem., 273, 2738, 10.1074/jbc.273.5.2738 Hollak, 1994, Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease, J. Clin. Invest., 93, 1288, 10.1172/JCI117084 Boot, 2006, CCL18: a urinary marker of Gaucher cell burden in Gaucher patients, J. Inherit. Metab. Dis., 29, 564, 10.1007/s10545-006-0318-8 Vellodi, 2005, Evaluation of three biochemical markers in the monitoring of Gaucher disease, J. Inherit. Metab. Dis., 28, 585, 10.1007/s10545-005-0585-9 McGovern, 2004, Lipid abnormalities in children with types A and B Niemann Pick disease, J. Pediatr., 145, 77, 10.1016/j.jpeds.2004.02.048 Zimmermann, 2012, Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study, J. Inherit. Metab. Dis., 36, 555, 10.1007/s10545-012-9529-3 Ratko, 2013, Enzyme-Replacement Therapies for Lysosomal Storage Diseases [Internet].; 2013 Jan. (Technical Briefs, No. 12.) Sanford, 2014, Elosulfase alfa: first global approval, Drugs, 74, 713, 10.1007/s40265-014-0210-z